Zeldox QTc Prolongation Is Less Severe Than Serlect, Pfizer Tells Committee

The QTc prolongation associated with Pfizer's antipsychotic Zeldox does not lead to the same clinical events as seen with Abbott/Lundbeck's antipsychotic Serlect, Pfizer told the Psychopharmacological Drugs Advisory Committee July 19.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet